Description

Cagrilintide represents a synthetic analogue of human amylin (islet amyloid polypeptide) engineered with specific modifications to enhance stability and extend duration of action. The compound maintains amylin receptor binding activity while demonstrating improved resistance to enzymatic degradation and enhanced pharmacokinetic properties. The peptide functions through specific binding to amylin receptors, leading to activation of signaling pathways that influence glucose homeostasis, gastric emptying, and satiety mechanisms. Research applications include investigation of amylin biology, glucose regulation mechanisms, and the role of amylin signaling in metabolic homeostasis. The compound’s enhanced stability profile makes it suitable for extended research protocols examining amylin receptor pharmacology and metabolic regulation pathways. For research use only.